Carboplatin as a potentiator of radiation therapy

Douple, Evan B.; Richmond, Robert C.; O’Hara, Julia A.; Coughlin, Christopher T.

doi:10.1016/0305-7372(85)90026-x

Cited by 147 publications

(40 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Laboratory studies have indicated a therapeutic potentiation when a single dose of the platinum complexes was combined with a single dose of radiation (16). Few data are available evaluating the fractionated use of drug and radiation; some of them suggest that most enhancement is obtained with a daily administration of the drug, before each irradiation ( 17-19, 23).…”

Section: Discussionmentioning

confidence: 99%

“…The combination of this drug and conventional or accelerated R T has been evaluated in several uncontrolled trials ( 12-15); encouraging results have been reported, but the optimal timing and dosage for the combined treatment have probably not been established. Preclinical studies suggest that both carboplatin and cisplatin, enhances the radiation effect (16). This enhancement seems to be maximal when the drug is present in the target cells at the moment of irradiation (17) and when the combined treatment is fractionated over a long time (18).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Concomitant Radiotherapy and Daily Low-Dose Carboplatin in Locally Advanced, Unresectable Head and Neck Cancer Definitive results of a phase I-II study

et al. 1994

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Concomitant Radiotherapy and Daily Low-Dose Carboplatin in Locally Advanced, Unresectable Head and Neck Cancer Definitive results of a phase I-II study

et al. 1994

View full text Add to dashboard Cite

“…Unfortunately, these two agents promote a significant normal tissue sensitization to radiotherapy as well, and chemoradiotherapy with taxanes is associated with a brisker local reaction than radiotherapy alone [25,26]. Cisplatin and carboplatin appear to be equally good radiation sensitizers, but they may be less effective than the taxanes [27,28]. On the other hand, platinums mediate significantly less normal tissue radiation damage than taxanes.…”

Section: Chemoradiotherapymentioning

confidence: 99%

Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment

et al. 2003

View full text Add to dashboard Cite

Since the publication of the Veterans Affairs study in the early 1990s, much has been learned regarding the role of chemotherapy, radiation therapy, and more importantly, the role of combined-modality treatment with chemoradiation in the therapy of locally advanced head and neck cancer. There continues to be widespread variation and controversy in the timing, schedule, and intensity of chemotherapy and chemoradiation. Herein, we present the various approaches currently used in the year 2003 with a specific emphasis on the role of sequential combined-modality therapy combining chemotherapy, chemoradiotherapy, and surgery in the treatment of these malignancies.

show abstract

“…Several studies (Groen et al, 1995;Kunitoh et al, 1997;Atagi et al, 2000) of concurrent daily carboplatin and radiotherapy have suggested that this combination is feasible and reasonably effective. Irinotecan and carboplatin have independently shown a synergistic effect with ionizing radiation in preclinical studies (Douple et al, 1985;Okishio et al, 1996). Based on these findings, we conducted a phase I trial of daily carboplatin and weekly irinotecan with concurrent thoracic radiotherapy for the treatment of locally advanced NSCLC in order to find the optimum dose of irinotecan and to estimate the antitumor activity and toxicity profile of this therapy.…”

mentioning

confidence: 99%

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer

et al. 2002

View full text Add to dashboard Cite

Dose-escalation study was performed to evaluate the maximum tolerated dose, recommended dose and toxicity profile of weekly irinotecan with daily carboplatin and concurrent thoracic radiotherapy in patients with locally advanced non-small-cell lung cancer. Thirty-one previously untreated patients with unresectable stage III non-small-cell lung cancer were enrolled in this study. Patients received weekly irinotecan plus carboplatin (20 mg m 72 daily for 5 days a week) for 4 weeks and thoracic radiotherapy (60 Gy in 30 fractions). The irinotecan dose was escalated from 30 mg m 72 in increments of 10 mg m 72 . Four irinotecan dose levels were given and 30 patients were assessable. Their median age was 62 years (range: 52 -72 years), 28 had a performance status of 0 -1 and two had a performance status of 2, 12 had stage IIIA disease and 18 had IIIB disease. There were 19 squamous cell carcinomas, 10 adenocarcinomas, and one large cell carcinoma. The dose-limiting toxicities were pneumonitis, esophagitis, thrombocytopenia and neutropenia. The maximum tolerated dose of irinotecan was 60 mg m 72 , with two patients developing grade 4 pulmonary toxicity and one patient died of pneumonitis (grade 5). The recommended dose of irinotecan was 50 mg m 72 . Other grade 3 or 4 toxicities were nausea and vomiting. Three patients achieved complete remission and 15 had partial remission, for an objective response rate of 60.0%. The median survival time was 14.9 months, and the 1-and 2-year survival rates were 51.6% and 34.2%, respectively. The study concluded that the major toxicity of this regimen was pneumonitis. This therapy may be active against unresectable non-small-cell lung cancer and a phase II study is warranted.

show abstract

Carboplatin as a potentiator of radiation therapy

Cited by 147 publications

References 43 publications

Concomitant Radiotherapy and Daily Low-Dose Carboplatin in Locally Advanced, Unresectable Head and Neck Cancer Definitive results of a phase I-II study

Concomitant Radiotherapy and Daily Low-Dose Carboplatin in Locally Advanced, Unresectable Head and Neck Cancer Definitive results of a phase I-II study

Docetaxel, Cisplatin, 5-Fluorouracil (TPF)-Based Induction Chemotherapy for Head and Neck Cancer and the Case for Sequential, Combined-Modality Treatment

Dose-escalation study of weekly irinotecan and daily carboplatin with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer

Contact Info

Product

Resources

About